新华社布加勒斯特2月27日电近日发表在国际学术期刊《微生物学前沿》上的一项新研究显示，在罗马 尼亚一处数千年历史的冰洞中发现的一种古老细菌对多种现代常用抗生素具有耐药性，表明细菌的耐药 性可以在自然演化中形成。 这种细菌发现于罗马尼亚一处冰洞约5000年前形成的冰层中。罗马尼亚科学院布加勒斯特生物研究所等 机构的研究人员在冰洞中钻取了一根长25米的冰芯，从中分离出多种细菌菌株，并对它们的基因组测序 分析，以研究其耐寒机制以及耐药性相关基因等。 研究人员利用10大类的28种临床常用或储备用抗生素对其中一种名为SC65A.3的嗜冷菌菌株进行测试， 发现它对其中的10种抗生素表现出耐药性，包括利福平、万古霉素和环丙沙星等用于治疗常见感染的药 物。SC65A.3也是第一种被发现对甲氧苄啶、克林霉素、甲硝唑等抗生素具有耐药性的嗜冷菌菌株。 研究还发现，SC65A.3携有百余个与耐药性相关的基因，还能抑制多种多重耐药"超级细菌"的生长，并 具备具有生物技术应用潜力的特殊酶活性。 研究人员认为，能够在寒冷环境存活的菌株可能是抗生素耐药性基因的"天然储库"。针对SC65A.3等古 老微生物的研究展现了抗生素耐药性如何在自然环 ...

研究还发现，SC65A.3携有百余个与耐药性相关的基因，还能抑制多种多重耐药"超级细菌"的生长，并 具备具有生物技术应用潜力的特殊酶活性。 研究人员认为，能够在寒冷环境存活的菌株可能是抗生素耐药性基因的"天然储库"。针对SC65A.3等古 老微生物的研究展现了抗生素耐药性如何在自然环境中演化出来，而这远早于现代抗生素的使用。 新华社布加勒斯特2月27日电（记者张改萍）近日发表在国际学术期刊《微生物学前沿》上的一项新研 究显示，在罗马尼亚一处数千年历史的冰洞中发现的一种古老细菌对多种现代常用抗生素具有耐药性， 表明细菌的耐药性可以在自然演化中形成。 这种细菌发现于罗马尼亚一处冰洞约5000年前形成的冰层中。罗马尼亚科学院布加勒斯特生物研究所等 机构的研究人员在冰洞中钻取了一根长25米的冰芯，从中分离出多种细菌菌株，并对它们的基因组测序 分析，以研究其耐寒机制以及耐药性相关基因等。 研究人员利用10大类的28种临床常用或储备用抗生素对其中一种名为SC65A.3的嗜冷菌菌株进行测试， 发现它对其中的10种抗生素表现出耐药性，包括利福平、万古霉素和环丙沙星等用于治疗常见感染的药 物。SC65A.3也是第一种被发现对甲 ...

新华社北京2月16日电（记者侠克）春节将至，节日期间饮食不规律、不节制，叠加作息紊乱、久坐少动等情况，可能引发各类健康问题。假期如 何科学饮食？记者采访了相关医学专家。 节日期间，亲朋好友相聚难免饮酒。北京友谊医院全科医学科主任医师乌依罕提示，头孢类、甲硝唑等药物与酒精会发生"双硫仑样反应"，引发 休克甚至死亡，服药前后7天严禁饮酒。慢性病患者，如高血压、糖尿病、肝病患者等饮酒会加重病情，需特别注意。 专家提示，食物塞进冰箱并不意味着万事大吉。冰箱中的李斯特菌，外号"冰箱杀手"，怕热却极其耐寒，在冰箱的冷藏温度下，不仅不"冬眠"， 反而能生长繁殖。如果剩菜没热透，这种菌进入人体，轻则腹泻，重则引发脓毒症或脑炎。"吃之前必须彻底加热。菜中心位置的温度要达到70℃ 以上，并且持续加热3分钟。只有这样，才能把李斯特菌和大部分病原菌彻底消除。"杨梓琪说。 此外，长期服药的患者特别是慢病患者，春节期间不可擅自停药。"尤其是高血压患者，血压的平稳是靠血液里药物浓度的恒定来维持的。停药一 天，药物浓度就像过山车一样跌下来，血压就会报复性反弹，增加心脑血管事件发生的风险。"乌依罕说，对于糖尿病患者，过年期间容易因生活 不规律 ...

Group 1 - A 30-year-old man in Nanjing experienced severe health complications after consuming alcohol while taking Metronidazole, leading to liver failure [1] - The patient was admitted with altered consciousness and strong alcohol odor, and after treatment, he developed hepatic encephalopathy, failing to recognize even his parents [1] - Medical staff managed to stabilize the patient after five days of intensive care, and he has since recovered and been discharged [1] Group 2 - Doctors warn against the dangerous combination of alcohol with certain medications, including Metronidazole and other drugs like hypoglycemics, antihypertensives, sedatives, and sleeping pills [1] - The principle of "do not drink alcohol while taking medication and do not take medication while drinking alcohol" is emphasized as a basic safety guideline [1]

Group 1 - A man in his 30s in Nanjing, Jiangsu, experienced liver failure after consuming metronidazole and alcohol, leading to a five-day hospitalization before stabilizing [1] - Medical professionals emphasize the dangers of combining metronidazole and alcohol, similar to the known risks of alcohol with cephalosporins [1] - The principle of "no alcohol with medication" is reiterated, highlighting that various medications, including antidiabetics, antihypertensives, sedatives, and sleeping pills, should not be mixed with alcohol [1]

Core Viewpoint - The company reported a significant decline in sales and profits for the first half of 2025, with a focus on adapting to market challenges and enhancing product offerings to stabilize its market position [1][2][3][4] Group 1: Financial Performance - The company achieved sales revenue of approximately HKD 2.147 billion, a year-on-year decrease of about 35.7% [1] - Profit attributable to equity holders was approximately HKD 283.5 million, down 58.7% year-on-year [1] - Earnings per share were HKD 0.0962, with an interim dividend of HKD 0.05 per share [1] Group 2: Infusion Business - The infusion sales volume decreased significantly, with approximately 715 million bottles (bags) sold, a decline of 37% year-on-year [1] - Sales revenue from infusion products was HKD 1.199 billion, down 45% year-on-year [1] - The company is focusing on digital transformation and market segmentation to enhance the sales of therapeutic infusion products [1] Group 3: Injectable and Oral Formulations - The sales volume of ampoule water injections increased by 7% to 17.818 million units, but sales revenue fell by 57% to HKD 157 million [2] - Notable growth in specific injectable products included a 61% increase in sales of mecobalamin injections and a 198% increase in sales of nebulized terbutaline solution [2] - Oral formulations achieved sales of HKD 296 million, a 16% increase year-on-year, with significant contributions from new products and contract renewals [2] Group 4: API and Export Business - The active pharmaceutical ingredients (API) segment saw sales of HKD 361 million, a decline of 9.6% year-on-year, with caffeine sales down 15% [3] - The company reported a 42% increase in export volume for infusion products, with a total of 7.361 million bottles (bags) exported [3] - The export sales of oral formulations reached a record high, with a staggering 9958% increase year-on-year [3] Group 5: Packaging Materials - The sales of pharmaceutical packaging materials reached HKD 101 million, reflecting a 7.1% year-on-year growth [4] - The company is enhancing its product offerings in rubber stoppers and multi-layer co-extruded films to improve market penetration [4]

Financial Performance - The company's revenue and net profit are expected to show growth in Q2 2025 compared to Q1 2025, with current order volumes meeting expectations [1] - Direct exports to the U.S. account for a low percentage of revenue, minimizing the impact of recent U.S. tariffs [1] - The company has faced a significant decline in net profit since its IPO, with the stock price currently less than one-third of the initial offering price of 50 CNY per share [2][3] Market Challenges - The stock price has been in a long-term decline, attributed to macroeconomic factors, market conditions, and industry developments [2][3] - The company’s internal value does not align with its market capitalization, facing issues such as insufficient information disclosure and a lack of recognized business logic [3] Product Development - The solid-state battery project has completed kilogram-level experiments and is currently in the process optimization phase, with no mass production yet [2][4] - The company is focusing on high-end raw materials and specialty intermediates in the pharmaceutical sector, aiming to expand its international market presence [4] Strategic Initiatives - The company plans to enhance its core competitiveness through improved main business operations and effective value communication to investors [2][3] - In the lithium battery materials sector, the company aims to reduce production costs through technological upgrades and expansion into upstream supply chains [4]

Core Viewpoint - The stock price of Hongyuan Pharmaceutical has experienced a dramatic decline since its IPO, dropping from 45 yuan to 13.7 yuan, raising concerns about the company's performance and underlying issues [1][5]. Group 1: IPO and Initial Performance - On March 20, 2023, Hongyuan Pharmaceutical listed on the Shenzhen Stock Exchange's ChiNext, but the stock price opened below the issue price, falling by 16.1% to close at 41.95 yuan on the first day [1][4]. - The issue price was set at 50 yuan per share with a price-to-earnings ratio of 41.21, significantly higher than the industry average of 26.98, contributing to investor skepticism and the subsequent price drop [4]. Group 2: Financial Performance - In the first half of 2023, the company's net profit attributable to shareholders plummeted by 78.51%, with cash flow from operating activities declining by 198.11% [5][7]. - For the entire year of 2023, the projected net profit is expected to be between 83 million and 97 million yuan, representing a year-on-year decline of 80.91% to 77.69% [5]. Group 3: Market Conditions and Competition - The decline in performance is attributed to intense competition in the lithium battery materials sector, where the price of lithium hexafluorophosphate has remained low, impacting profitability despite increased sales volume [7]. - Additionally, the pharmaceutical sector faces heightened competition due to national procurement and medical insurance policies, leading to decreased unit prices for products like metronidazole, further eroding profit margins [7]. Group 4: Stock Price Decline - Following the initial high of 45 yuan, the stock price has continued to decline, reaching a low of 11.41 yuan by September 10, 2024, and closing at 13.28 yuan on May 7, 2025, representing a drop of over 70% from the issue price [7][8]. Group 5: Fundraising and Investor Sentiment - The company raised 15.45 billion yuan through its IPO, more than double the expected amount, but faced criticism for investing 2 billion yuan in financial products the day after listing, leading to accusations of "money-grabbing" [9][10]. - Investors have suffered significant losses, with many expressing dissatisfaction in online forums regarding the company's stock performance and financial results [12].

Group 1: Company Overview and Market Position - The company is a leading player in the nitroimidazole antibiotic sector, particularly known for its metronidazole raw materials, with the longest industrial chain and the most product varieties globally [2][3] - The main products include metronidazole and its derivatives, with the largest global production capacity and market share, recognized for product quality and cost competitiveness [2][3] Group 2: Performance and Challenges - In 2024, the company faced a significant decline in performance, primarily due to the lithium hexafluorophosphate and metronidazole businesses, with a notable drop in sales prices despite increased sales volume [3][4] - The lithium battery materials sector experienced intensified competition, leading to lower sales prices for lithium hexafluorophosphate, which adversely affected profitability [3][4] - The decline in metronidazole profitability was attributed to increased competition and a decrease in product unit prices, which fell more than the reduction in unit costs [3][4] Group 3: Strategic Responses - The company has implemented a multi-faceted strategy to address current challenges, including cost optimization through production line upgrades and supply chain management [3][4] - Increased investment in research and development to accelerate product technology upgrades and new product development is a key focus [3][4] - Efforts to expand into high-margin product markets are underway to enhance overall profitability [3][4] Group 4: Financial Health and Future Outlook - The company maintains a healthy cash flow and robust financial structure, ensuring sufficient reserves for future operations and investment plans [4] - There are no current risks of delisting as per the Shenzhen Stock Exchange regulations [4] - The company has received approvals for new drug applications, including for sitagliptin phosphate and celecoxib, indicating ongoing product development [4]

股票简称：宏源药业 股票代码：301246 湖北省宏源药业科技股份有限公司 Hubei Hongyuan Pharmaceutical Technology Co., Ltd. （湖北省罗田县凤山镇经济开发区宏源路8号） 首次公开发行股票并在创业板上市 之 上市公告书 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 二零二三年三月 特别提示 湖北省宏源药业科技股份有限公司（以下简称"宏源药业"、"本公司"或 "发行人"、"公司"）股票将于 2023 年 3 月 20 日在深圳证券交易所创业板上 市，该市场具有较高的投资风险。创业板公司具有业绩不稳定、经营风险高、退 市风险大等特点，投资者面临较大的市场风险。投资者应充分了解创业板市场的 投资风险及本公司所披露的风险因素，审慎做出投资决定。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与本公司首次公开发行 股票并在创业板上市招股说明书中的相同。 1 | 特别提示 1 | | --- | | 目 录 2 | | 第一节 ...